PODD · News · 20260806N

Type 2 Retention Challenges

INSULET CORP · 2026-08-06 · Importance 40 · Surprise 42

Insulet attributed the U.S. outlook reduction to weaker-than-anticipated retention and utilization among Type 2 diabetes patients. Management identified execution challenges during the initial 90-day onboarding period as a cause of the weaker customer performance. The company plans to expand customer care, modify sales-force compensation, refine sampling, and roll out the Omnipod Discover platform. International growth expectations were raised while U.S. and total-company 2026 revenue-growth expectations were reduced.

Key facts

• Insulet's stock drop of 21.9% was reported after cutting its 2026 revenue outlook on weaker Type 2 retention; the company reported Q2 sales of $801.7 million and net income of $95.0 million. source